Check-Cap (NASDAQ:CHEK) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK – Free Report) in a research report report published on Tuesday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 2.0 %

NASDAQ:CHEK opened at $1.45 on Tuesday. Check-Cap has a 1-year low of $1.13 and a 1-year high of $3.94. The firm has a market capitalization of $8.48 million, a price-to-earnings ratio of -0.48 and a beta of 0.36. The business’s fifty day moving average price is $1.73 and its 200 day moving average price is $2.05.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

See Also